- TheStreet.com•3 hours ago
Leerink trimmed its price target on Gilead Sciences (GILD) stock today as it anticipates lower revenue from HIV sales in the future.
- Barrons.com•4 hours ago
Shares of Gilead Sciences (GILD) have dropped 19% so far this year thanks to disappointing sales of its hepatitis-C treatments. Now, Leerink's Geoffrey Porges and Bradley Canino have cut their price target on the biotech giant thanks to signs that its new HIV drug sales haven't been as strong as they originally modeled. As a result of our updates, we continue to expect Gilead’s domestic HIV volume to grow steadily and sustainably but now forecast a slightly lower Revenue/TRx trend given slower-than-expected switching to TAF based regimens from legacy combinations.
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||81.62 x 300|
|Ask||81.63 x 700|
|Day's Range||81.27 - 82.10|
|52wk Range||77.92 - 113.31|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||7.15|
|Avg Vol (3m)||10,176,060|
|Dividend & Yield||1.88 (2.32%)|